Meeting Materials

Abstract: The goal of this study was to explore the efficacy and feasibility of an integrated, prescriptive, and trackable 30-day wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.

<p>Abstract: Background: HP-3070, a once-daily asenapine transdermal system, is FDA-approved for adults with schizophrenia. The Positive and Negative Syndrome Scale (PANSS) score’s five-factor structure can assess treatment efficacy across different domains.

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT), which are associated with worse prognosis and greater functional burden.

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT). For such patients, early optimized treatment is critical.

<p>Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new formulation of aripiprazole monohydrate intended for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar I disorder (BP-I).

<p>Abstract: Introduction: The aim of this pooled analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents (13-17 years) and young adults (18-25 years).

Abstract: Introduction: The aim of this analysis was to evaluate the efficacy and safety of lurasidone in bipolar depression in youth and young adult patients (10-30 years old).

<p>Abstract: Background/Objective: Atypical long-acting injectable (aLAI) antipsychotics are efficacious treatments for schizophrenia; however, a deeper understanding of the real-world outcomes resulting from their use is needed.

<p>Abstract: Background: In the 5-week, randomized, double-blind, placebo-controlled, phase 2 EMERGENT-1 study (NCT03697252), the M1/M4 preferring muscarinic receptor agonist KarXT met primary and secondary efficacy endpoints and was safe and generally well tolerated.

Abstract: Purpose: Emotional lability (EL) is commonly seen in individuals with attention-deficit/hyperactivity disorder (ADHD).

<p>Abstract: Background/Objective: The South Carolina Department of Mental Health instituted a Community Telepsychiatry Program (CTP) to increase patient access to mental health practitioners.

Abstract: BACKGROUND: Adults with major depressive disorder with acute suicidal ideation or behavior (SIB; MDSI) initiated on esketamine or traditional therapies were described to understand variation in patient profiles.

Abstract: BACKGROUND: Treatment patterns among adults with major depressive disorder with suicidal ideation or behavior (MDSI) started on esketamine or traditional therapies were described to understand treatment profiles.

Abstract: BACKGROUND: Access to esketamine therapy for treatment-resistant depression (TRD) is available only through certified treatment centers in the US. Therapy starts with induction comprising 8 treatment sessions within 4 weeks.

Abstract: Background: Valbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD). Data from a 48-week, open-label study of valbenazine (KINECT 4 [NCT02405091]) were analyzed post hoc to assess treatment response patterns.

<p>Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder.

Abstract: Background: Major depressive disorder (MDD) is associated with elevated health care and societal cost, increased morbidity and mortality, and diminished quality of life. First line treatments include pharmacotherapy and psychotherapy.

<p>Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder.

Abstract: Introduction: This post hoc analysis evaluated response to open-label lower-sodium oxybate (LXB; Xywav®) treatment on Epworth Sleepiness Scale (ESS) scores in a phase 3 clinical trial (NCT03533114).

Abstract: Introduction: This post hoc analysis evaluated response to lower-sodium oxybate (LXB; Xywav®) treatment on Idiopathic Hypersomnia Severity Scale scores in a phase 3 clinical trial (NCT03533114).

Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD).

Abstract: Introduction

<p>Abstract: Introduction: Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.

Abstract: Background: While insomnia occurs in half of adults with type 2 diabetes (T2D), its incremental economic impact in this population is unclear. Objectives: This study evaluated on healthcare resource utilization (HCRU) and costs in patients with T2D and comorbid insomnia.

Abstract: Background: Insomnia contributes to cognitive decline, increased fall risk, and nursing home placement in patients with Alzheimer’s disease and related dementias (ADRD).

Abstract: Almost half of patients with cancer have trouble sleeping and treatment can exacerbate these problems. Objectives: This study evaluated healthcare resource utilization (HCRU) and costs associated with insomnia in patients undergoing cancer treatment.

Background: To describe lemborexant and daridorexant for insomnia treatment using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH).

Abstract: Background: Major depressive disorder (MDD) is a common brain health disorder that affects at least 1 in 5 individuals in the United States (US) during their lifetime. Adults with MDD were surveyed to rate the importance of desirable attributes associated with a new therapy for MDD.

Abstract: Objective: WATERFALL (Phase 3; NCT04442490), adult patients with moderate to severe MDD who received zuranolone 50mg vs placebo showed statistically significant improvement in depressive symptoms (assessed by change from baseline [CFB] in HAMD-17 total score) at Day 15 (-1.7; p-value =

Abstract: Purpose: To examine real-world esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., sedation, dissociation, increased blood pressure [BP]) and serious adverse events (SAEs) during the first 12 treatment sessions.

Abstract: Background: People living with bipolar I disorder (BD-I) have a higher risk of obesity than the general population. While outcomes associated with obesity are well documented in general, less is known about the burden of obesity among adults with BD-I.

Abstract: Background: Psychiatric nurse practitioners (NPs) need access to appropriate, up-to-date educational materials to help them successfully diagnose and clinically manage their patients.

Abstract: As insomnia affects elderly more than younger adults, therapeutic options with limited safety risks are needed to treat this patient group. We report elderly subgroup analyses from a Phase-3 trial with daridorexant.

Abstract: Trazodone is indicated for depressive disorder (150-400 mg/day) but is often prescribed off-label to treat insomnia at “low dose” ( < 150 mg/day) despite recommendations against its use for insomnia.

Abstract: Introduction

Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. This post-hoc analysis investigated effect size and number needed to treat (NNT) for d-ATS.

<p>Abstract: Background: In clinical trials of valbenazine, which is approved for once-daily treatment of tardive dyskinesia (TD), psychiatric stability was assessed along with global changes in TD.

Abstract: Introduction: Migraine with psychiatric comorbidities has been associated with increased disability, pain, and reduced quality-of-life.

Abstract: Introduction: Major depressive disorder (MDD) is a common migraine comorbidity. Fremanezumab, a humanized monoclonal antibody selectively targeting calcitonin gene-related peptide, is approved for preventive treatment of episodic and chronic migraine (EM/CM) in adults.

Abstract: In recent years, demand for psychiatric care has been rapidly growing. At the same time, estimates show that 122 million people in the US reside in mental health professional shortage areas. Additional mental health providers are urgently needed to fill these deficits.

<p>Abstract: BACKGROUND: Quality measures were compared between patients initiated on second-generation long-acting injectable antipsychotics (SGLAIs) and oral atypical antipsychotics (OAAs).

<p>Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder.

<p>Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder.

<p>Abstract: Introduction: Here we provide a brief review of the discovery of ulotaront and preclinical research suggesting efficacy in schizophrenia, leading to the first clinical trial of ulotaront resulting in FDA Breakthrough Therapy Designation.

<p>Abstract: Introduction: Here we summarize ongoing clinical research characterizing the efficacy and safety of ulotaront as a member of the novel trace amine-associated receptor 1 (TAAR1) agonist class.

<p>Abstract: Background: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that substantially impacts patients’ lives. This study assessed psychological and social aspects of TD from patient and caregiver perspectives to better understand the stigma surrounding TD.

<p>Abstract: Introduction: Advanced age and female sex are risk factors for tardive dyskinesia (TD). This post hoc analysis assessed the long-term efficacy and safety of deutetrabenazine, an FDA-approved treatment for TD in adults, in women who were postmenopausal.

<p>Abstract: Aim Negative symptoms of schizophrenia (NSS) have been linked to poor quality of life (QoL) and impaired functional outcomes. A systematic literature review was performed to identify measures used to assess QoL and functional outcomes in studies conducted in people with NSS.

Abstract: Introduction: A concern with sedative-hypnotic medication for the treatment of insomnia is the development of tolerance.

Abstract: Introduction: Abnormal dreams and nightmares are reported by patients with insomnia both before and after treatment with hypnotics. Dual orexin receptor antagonists such as lemborexant (LEM) increase rapid eye movement sleep, during which dream content recall is more likely.

<p>Abstract: Background: Although long-acting injectable antipsychotics (LAIs) are often reserved for patients with chronic schizophrenia, emerging evidence suggests that LAIs may reduce the risk of treatment failure (TF) or relapse in patients with shorter duration of illness.

<p>Abstract: Purpose: Paliperidone palmitate once-every-3-months (PP3M) is a long-acting injectable antipsychotic indicated for adults with schizophrenia adequately treated (AT) with once-monthly paliperidone palmitate (PP1M) for ≥4 months.

<p>Abstract: Background: Tardive dyskinesia (TD), an iatrogenic movement disorder associated with antipsychotic agent (AP) use, is predicted to increase in prevalence, but real-world data are lacking.

Abstract: Background: Although major depressive disorder (MDD) is associated with high economic burden, short-term healthcare resource utilization (HCRU) is poorly understood in patients newly diagnosed with MDD.

Abstract: Purpose: Immediate-release methylphenidate (IR MPH) is sometimes dosed in the afternoon to extend the duration of effect of a morning-dosed extended-release (ER) MPH for attention-deficit/hyperactivity disorder (ADHD).

Abstract: Aim: To gain insights on the real-world treatment experiences of patients with major depressive disorder (MDD) through PatientsLikeMe (PLM), an online community platform.

Abstract: Pharmacogenetic testing (PGx) has been shown to decrease healthcare resource utilization in a variety of settings, including behavioral health1.

Abstract: OBJECTIVES: Treatment persistence (i.e., measure of real-world treatment utilization relative to patient preference) with pimavanserin (PIM), the only FDA approved atypical antipsychotic (AAP) for hallucinations and delusions associated with Parkinson’s Disease Psychosis (PDP) vs.

Abstract: Introduction: Headache is a frequently reported treatment-emergent adverse event (TEAE) in clinical trials of hypnotics. We evaluated the frequency and timing of TEAEs of headache in the Phase 3 clinical program of lemborexant (LEM), a dual orexin receptor antagonist.

Abstract: Introduction: Study E2006-G000-303 (Study 303; NCT02952820) showed lemborexant (LEM) provided significant benefit vs placebo (PBO) on patient-reported sleep and fatigue severity, based on the Insomnia Severity Index (ISI) and Fatigue Severity Scale (FSS), respectively.

Abstract: Background: Treatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed.

Abstract: Background: Patients with major depressive disorder (MDD) who have inadequate response to antidepressant treatment (ADT) may require adjunctive therapy.

Abstract: Background: Adjunctive cariprazine was evaluated in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT), stratified by baseline anxiety.

<p>Abstract: Purpose: Paliperidone palmitate once-every-3-months (PP3M), a long-acting injectable antipsychotic, is indicated for adults with schizophrenia adequately treated (AT) with paliperidone palmitate once-monthly (PP1M) for ≥4 months and in whom the last 2 PP1M doses were the same.

Abstract: Purpose: This subgroup analysis of SUSTAIN-3 (NCT02782104), an ongoing open-label extension study of esketamine nasal spray (ESK), assessed long-term safety and efficacy of flexibly dosed ESK in combination with an oral antidepressant (OAD) in Black and/or African American (Black/AA) pa

<p>Abstract: Objective: To examine the regional variation in schizophrenia care, as measured by antipsychotic (AP) utilization, healthcare resource utilization (HRU) and associated costs, and quality measures, among US Medicare beneficiaries.

Abstract: Objective: This systematic review and meta-analysis synthesized the evidence from randomized controlled trials (RCTs) to compare depressive symptom reduction and all-cause dropout rates between depressed patients receiving vitamin D supplements and placebo.

<p>Abstract: Relapse (i.e., acute exacerbations of symptoms) is common among patients living with schizophrenia leading to employment, economic, and social instability. The objective of this study was to understand patient characteristics related to frequent relapse.

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety disorders. Traditionally, it is administered as immediate-release tablets given two or three times daily for short-term anxiety relief, in doses ranging from 1-10-mg/day.

Abstract: Lorazepam, traditionally administered as immediate-release tablets, is an allosteric GABA-receptor modulator approved for the treatment of anxiety disorders. A once-daily, extended-release formulation of lorazepam capsules has been developed to deliver more consistent drug levels.

Abstract: Background Borderline Personality Disorder (BPD) is a heterogeneous disorder. The current study used network analysis of Electronic Health Record (EHR) data to explore associations between symptom groupings in patients diagnosed with BPD.

<p>Abstract: Background Cognitive dysfunction is a core feature of schizophrenia and is associated with worse long-term functioning. No therapies exist to improve cognitive function to a clinically meaningful degree.

<p>Abstract: Currently-approved treatments for schizophrenia have demonstrated effectiveness for treating positive symptoms. There is a need to develop effective treatments for negative symptoms, which if left untreated, may indicate a poorer clinical course.

Abstract: Oral donepezil is widely prescribed for dementia of the Alzheimer’s type. Donepezil transdermal system (TDS; Adlarity®) was also recently approved.

Abstract: Donepezil transdermal system (TDS; Adlarity®) is approved for dementia of the Alzheimer’s type.

Abstract: Objective: Ketamine is recognized as a rapidly acting antidepressant; however, discrepancies exist between the "Efficacy" reported in research studies (70-85%) versus significantly lower "Effectiveness" (18.3-45.5%) reported in community-based settings.

<p>Abstract: Introduction: Schizophrenia affects over 3 million people in the United States. Despite data supporting the use of long-acting injectable antipsychotic agents (LAIs), myths and misconceptions commonly held by physicians lead to underutilization.

<p>Abstract: Introduction: Treatment nonadherence in schizophrenia is a continuing challenge, but can be improved with use of long-acting injectable antipsychotic agents (LAIs).

<p>Abstract: Objective: Cultural differences impact schizophrenia management across countries and may complicate the evaluation of new therapeutics.

<p>Abstract: Introduction: Healthcare professionals (HCPs) face unique challenges when managing patients with schizophrenia.

Abstract: Background: Prescription digital therapeutics (PDTs) are U.S. Food and Drug Administration-authorized software-based treatments delivered on mobile devices. The reSET-O PDT for patients with opioid use disorder (OUD) is linked to a clinician-facing dashboard (Pear.MD).

Abstract: Aim: Prescription digital therapeutics (PDTs) are software-based treatments evaluated for safety and effectiveness by the FDA. This study evaluated associations between age and levels of PDT engagement and treatment retention among patients with opioid use disorder (OUD).

<p>Abstract:</p>

Abstract: Introduction: Sodium oxybate, a recommended narcolepsy treatment, is a high sodium–containing drug with consequent label warnings. The sodium-hypertension relationship is well established.

Abstract: A 70s-aged female Parkinson’s Disease patient was admitted for encephalopathy, affective changes, and hallucinations. She was anxious, but intermittently alert and oriented.

<p>Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, intended for the treatment of schizophrenia and maintenance monotherapy treatment of bipolar I disorder (B

<p>Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, intended for the treatment of schizophrenia and maintenance monotherapy treatment of bipolar I disorder (B

Abstract: Background: The long-term impact, burden, and treatment patterns of tardive dyskinesia (TD) are not well understood. Patient- and clinician-reported outcomes are important in determining the severity and multidimensional impact of TD on patients.

<p>Abstract: Background: Tardive dyskinesia (TD) substantially impacts patients’ ability to function in their daily lives. This study assessed physical functioning of patients with TD from the perspectives of patients and caregivers.

Abstract: Background

<p>Abstract: Background: Emraclidine is a novel, highly selective, M4 muscarinic receptor positive allosteric modulator in development for treating schizophrenia. Here, we describe safety, tolerability, and pharmacodynamic results from Part B of a two-part, phase 1b trial (NCT04136873).

Abstract: COMP360 is a synthetic purified form of psilocybin in development for treatment of adults with treatment-resistant depression (TRD). COMP360 psilocybin therapy combines oral COMP360 psilocybin with psychological support.

<p>Abstract: Background TV-46000 is a risperidone extended-release suspension for subcutaneous administration in development for treatment of patients with schizophrenia. TV-46000 is based on an innovative copolymer drug delivery technology licensed from Medincell (Jacou, France).

Abstract: Introduction: The aim of this research was to gain caregiver insights on their previous use and current attitudes of naloxone to reverse opioid overdoses, including different routes for administration.

Abstract: Introduction: The TENOR study examines the impact of transitioning from sodium oxybate (SXB) to lower-sodium oxybate (LXB; 92&#37; less sodium than SXB) in a real-world setting.

Abstract: Introduction: Idiopathic hypersomnia is characterized by excessive daytime sleepiness, sleep inertia, and in some patients, long sleep time; these symptoms may partially overlap with psychiatric disorders.

Abstract: Background: We present a case study to demonstrate how patient-reported outcomes (PROs) are used in mental health, and their impact on patient health and engagement.

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety. The existing formulation delivers immediate-release lorazepam to provide short-term anxiety relief at doses ranging from 1-10-mg/day, given in tablets two to three times daily.

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety and primarily administered as immediate-release tablets. The current immediate-release formulation is conventionally given in doses ranging from 1-10-mg/day, two or three times a day.

Abstract: Statistics have shown over time that teaching is one of the most stressful occupations.Recently, mindfulness training (MT) has emerged as a useful and tested means to support educators in terms of their emotional coping skills, mental health status, stress reduction and working motivati

Abstract: Background

Abstract: Introduction: There is evidence that insomnia patients with objective short-sleep duration (I-SSD; total sleep time [TST] < 6hrs) may respond less to behavioral therapy for insomnia than insomnia patients with objectively longer, more normal-sleep duration (TST≥6hrs).

Abstract: Introduction: There is a well-established reciprocal relationship between pain and poor sleep.

Abstract: Approximately one third of major depression cases will not remit even with two or more medication trials, defined as treatment-resistant depression (TRD). The newest FDA-approved treatment for TRD in adults, esketamine, has a unique mechanism with comparatively rapid clinical effect.

<p>Abstract: Introduction: Here we summarize preclinical results assessing the effects of ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist under investigation for the treatment of schizophrenia, on weight and metabolic parameters.

Abstract: Background: Treating tardive dyskinesia (TD) with anticholinergics is a common practice, despite the lack of supportive evidence and potential to worsen TD.

<p>Abstract: Antipsychotic treatment can help improve outcomes in schizophrenia by reducing the risk of relapse and psychiatric hospitalization, and increasing rates of remission and recovery, particularly when used early in the disease course.

Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years).

Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults.

Abstract: Daridorexant improved night and daytime symptoms of insomnia disorder in two parallel, phase 3, 12-week studies with maintained improvements over a 40-week extension study. The largest effect in the 12-week studies occurred with daridorexant 50 mg.

Abstract: Purpose:

Abstract: Background: Patient life engagement is a broad term describing positive health aspects across four domains (emotional, physical, social, cognitive).

Abstract: Background: Obstructive sleep apnea (OSA) is a sleep disorder that is often comorbid with psychiatric disorders. Excessive daytime sleepiness (EDS) is common in both psychiatric disorders and OSA.

Abstract: Background: Obstructive sleep apnea (OSA) is a common sleep disorder that is often associated with medical and psychiatric comorbidities. Patients with OSA experience many symptoms that can be burdensome and affect their quality of life.

Abstract: Background and Introduction: PH94B is an investigational pherine nasal spray thought to regulate the olfactory-amygdala circuits of fear and anxiety without direct GABA-A receptor activation or binding to other central nervous system receptors.

Abstract: Background: Anxiety is a prevalent symptom among patients with major depressive disorder (MDD).

<p>Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder as monotherapy and as adjunctive therapy with lithium or valproate.

<p>Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance monotherapy for bipolar I disorder (BP-I) in adults .

<p>Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance monotherapy for bipolar I disorder (BP-I) in adults (&gt;=18 years).

Abstract: Background:

Abstract: Introduction: Most patients with major depressive disorder (MDD) fail first-line antidepressant treatment. Pharmacogenomic (PGx) testing may improve drug selection and/or dosing.

<p>Abstract: This model examined annual drug treatment costs for aripiprazole once-monthly (AOM) 400 mg and aripiprazole lauroxil (AL) 882 mg among adult patients with schizophrenia or bipolar I disorder.

<p>Abstract: Background: Aripiprazole 2-month Ready to Use 960 mg (ARI 2M RTU) is a long-acting injectable antipsychotic (LAI) in development for treatment of schizophrenia and maintenance treatment of bipolar I disorder.

Abstract: Objectives: To evaluate seltorexant effect in improving depressive symptoms beyond sleep-related improvement in major depressive disorder (MDD) using MADRS-WOSI (MADRS without sleep item) and MADRS-6 (6 core depression items).

Abstract: Background: Atypical antipsychotics may be efficacious in the treatment of borderline personality disorder (BPD). This double-blind, Phase 2 study (NCT04100096) evaluated the efficacy and safety of brexpiprazole in BPD treatment.

Abstract: Background: Atypical antipsychotics may be efficacious in the treatment of borderline personality disorder (BPD). This study assessed the safety, tolerability and efficacy of brexpiprazole in patients with BPD (NCT04186403).

<p>Abstract: Introduction No effective pharmacological treatments are available for cognitive impairments in schizophrenia.

<p>Abstract: Introduction Iclepertin (BI 425809), a novel glycine transporter-1 inhibitor, had pro-cognitive effects in patients with schizophrenia in a Phase II trial; however, the effects of concurrent cognitive stimulation are unknown.

<p>Abstract: Rationale Patients and clinicians may have different expectations concerning their priorities and perspectives for treating schizophrenia. For example, patient accounts of living with schizophrenia often go beyond the constraints of clinical descriptors.

Abstract: Introduction: Accurate assessment of disability associated with Parkinson’s Disease Psychosis (PDP) is essential and has been poorly studied. Patients often have poor insight on impact of PDP on daily function.

<p>Abstract: Objective: The prevalence of obesity and associated metabolic disorders in patients with schizophrenia or bipolar 1 disorder is approximately 60%.

Abstract: Background: Despite available guidelines, identifying and managing post-traumatic stress disorder (PTSD) in clinical practice remains challenging due to the heterogenous disease manifestation.

Abstract: Introduction: Effects of cariprazine on weight and metabolic parameters were evaluated.

Abstract: Background: Treating patients with bipolar I disorder (BP-I) with an agent that is only effective against one pole may elicit treatment-emergent affective switch (TEAS), or worsening of the opposite pole.

Abstract: Background: Bipolar mania and mixed episodes can be associated with hostility and agitated behavior. Effects of cariprazine on these symptoms were evaluated in this post hoc analysis.

Abstract: Introduction: Treatment non-response may indicate need for further clinical management; thus, early prediction of treatment response can aid clinical decision-making, including dose titration.

Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the large-scale Komodo® Healthcare Map database.

Abstract: Background

Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) in a laboratory classroom setting.

Abstract: Introduction: The Coronavirus-19 (COVID-19) pandemic represented an unprecedented challenge to the mental health of the global population.

Abstract: Introduction: Pimavanserin 34 mg is approved in the US to treat hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP).

<p>Abstract: Background: Treatment with long-acting injectable antipsychotic agents (LAIs) has been shown to improve outcomes in schizophrenia; however, many healthcare providers continue to reserve LAIs for patients with severe disease or adherence issues.

Abstract: Background:

Abstract: Background: Agitation is common in Alzheimer’s dementia, and one of the most stressful aspects of care. The aim of this study was to confirm the efficacy, safety and tolerability of brexpiprazole in patients with agitation in Alzheimer’s dementia.

Abstract: Introduction: Major depressive disorder (MDD) is associated with humanistic and economic burden. Little is known about this burden among those with treatment failure.

Abstract: Introduction: Patients with major depressive disorder (MDD) often cycle through multiple treatments prior to receiving an adjunctive atypical antipsychotic (AA).

<p>Abstract: Aims: This 12-week, phase 3, multicenter, double-blind study (NCT03187769) evaluated the effect of combination olanzapine and samidorphan (OLZ/SAM) vs olanzapine on weight in early-in-illness patients with schizophrenia, schizophreniform disorder, or bipolar I disorder (BD-I).

Abstract: Background: Patients with MDD often do not respond to antidepressant (ADT) monotherapy. Cariprazine (CAR) is under investigation as adjunctive therapy for patients with MDD.

<p>Abstract: Background: Safety of cariprazine in patients with major depressive disorder (MDD) with inadequate response to antidepressants was evaluated.

Abstract: Background: The efficacy of adjunctive cariprazine treatment on depressive symptoms was evaluated in patients with major depressive disorder (MDD) and inadequate response to antidepressant treatment (ADT), stratified by baseline anxiety level.

Abstract: Background: Clinical trial results often report mean changes, though individual responses may be more valuable in clinical practice.

Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibits cytochrome P450-1A2, which is responsible for caffeine metabolism.

Abstract: Introduction

Abstract: Introduction

Abstract: Background: In STAR*D, following non-remission with an SSRI, remission rates for second line treatments were ~ 25% regardless of the switch strategy employed. Antidepressants with novel mechanisms may improve outcomes in MDD.

Abstract: Background: Innovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed.

Abstract: Background: Individuals receiving treatment for major depressive disorder (MDD) continue to face multiple disease or treatment-related issues.

<p>Abstract: Background: Females are often underrepresented in clinical trials of antipsychotic treatment of schizophrenia.

Abstract: Background: AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist.

Abstract: This study investigated the implementation of depression screening with the Patient Health Questionnaire (PHQ-9) in inpatient psychiatric care in a tri-state hospital group, Oceans Healthcare.

Abstract: Introduction

Abstract: Introduction

Abstract: Introduction

Abstract: Background: Mild cognitive impairment (MCI) is characterized by cognitive and memory deficits that may affect instrumental daily activities (iADLs). Dementia is characterized by cognitive decline that does affect ADLs.

There is limited information on the use of monoamine oxidase inhibitors (MAOIs) with other psychotropic medications due to concern for drug-drug interactions in precipitating serotonin syndrome (toxicity).

Abstract: Introduction: The SEGUE study examines safety, tolerability, effectiveness, and treatment optimization in participants with narcolepsy transitioning from sodium oxybate (SXB) to lower-sodium oxybate (LXB; 92&#37; less sodium than SXB).

Abstract: Introduction: The TENOR study examines the transition from sodium oxybate (SXB) to lower-sodium oxybate (LXB; 92% less sodium than SXB) in a real-world setting.

Bipolar disorder, previously known as manic depression, is a serious mental illness associated with extreme mood swings and manic/hypomanic episodes that interfere with an individual’s ability to fully function on a day-to-day basis.

Abstract: Objective: This study evaluated the 2-year effectiveness of the first FDA-authorized prescription digital therapeutic (PDT) for adults with chronic insomnia that delivers evidence-based treatment (Somryst).

<p>Successful management of schizophrenia remains an elusive target for many clinicians. High rates of undertreatment and nonadherence result in poor outcomes among many patients, with significant consequences for morbidity and mortality.

Excessive daytime sleepiness, or EDS substantially impacts individuals with psychiatric disorders, leading to heightened disability and mortality rates compared to the general population.

Abstract: Introduction: Chronic insomnia (CI) often co-occurs with depression and anxiety.

Tardive dyskinesia, or TD, is a side effect of treatment with antipsychotic medications, resulting in repetitive and uncontrollable movements of the body and face.

Abstract: Medical students are prone to anxiety and depression, largely due to the nature of their coursework. During the COVID-19 pandemic, many medical students were required to study from home without being involved in clinical practice.

Abstract: Introduction: Drug-induced movement disorders (DIMDs), including tardive dyskinesia (TD), are commonly associated with dopamine receptor-blocking medications. Benztropine is beneficial in treatment of some DIMDs but is not recommended for TD and may exacerbate TD.

<p>Introduction Experiential negative symptoms (ENS) are a major schizophrenia associated burden. Perceptions about the inability of people with schizophrenia to use technology are a barrier for adoption of accessible digital treatments.

<p>BACKGROUND: Sublingual dexmedetomidine is a selective alpha2-adrenergic receptor agonist recently approved for the treatment of agitation in adults with schizophrenia or bipolar disorder.

Abstract: Nearly 15 million adults in the US have experienced one or more major depressive disorder (MDD) events in the past year; primary care clinicians are the first line for initial diagnosis and management.